The next-generation sequencing test also determines the cancer cells’ microsatellite instability status and tumor mutational ...

The German arms manufacturer Rheinmetall and Finnish microsatellite manufacturer ICYEYE will work together, with support from ...

The 5-year disease-free survival rate was 63.3% for patients with microsatellite instability and 41.4% for patients with microsatellite-stable disease. Microsatellite instability (MSI) is a “striking” ...

The FDA recently approved a phase 2 clinical trial to investigate the efficacy of leronlimab in patients with relapsed or ...

Although pembrolizumab is approved for deficient mismatch repair or microsatellite instability-high (dMMR/MSI-H) tumors regardless of histology, there is a paucity of data to support its effectiveness ...

They help researchers identify desirable traits, such as disease resistance or yield potential, by linking specific ...

Werner helicase (WRN) inhibitors are already being evaluated in phase I clinical trials in patients with tumors that have ...

as well as solid tumors found to have high microsatellite instability or mutational burden. Second, 23ME-01473 is being ...

GRANITE vs. control in all treated population (HR=0.73 [90% CI, 0.44, 1.21]) -- -- 50% relative risk reduction of progression ...

Agenus Inc (AGEN) reports progress in cancer treatment trials amid financial constraints and strategic partnership ...

Syndax Pharmaceuticals advances Revumenib for relapsed AML with FDA decision pending. See why SNDX stock is a key player in ...

Research and development (R&D) expenses: R&D expenses for the three months ended September 30, 2024, were $14.4 million, compared to $14.2 million for the same period in 2023. The increase was due ...